Home › Companies › UPB

Upstream Bio

Market cap $115M 54.8M shares (10-Q, Nov 6, 2026) × $2.10 close Nov 17, 2026

Most recent annual filing: 2026-03-26

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. Verekitug filingLate 2026 to early 2027Verekitug filing, Late 2026 to early 2027, notable
  2. Upstream Bio financing2027Upstream Bio financing, 2027, notable
  3. BEL512 Ph3 readout2027BEL512 Ph3 readout, 2027, notable
  4. Verekitug trial start1Q 2027Verekitug trial start, 1Q 2027, routine
  5. Verekitug — COPD VENTURE Ph22H 2027Verekitug — COPD VENTURE Ph2, 2H 2027, major
  6. Verekitug — VALOUR extension readout2H 2027Verekitug — VALOUR extension readout, 2H 2027, material
  7. Verekitug corporate updateOct 11, 2027Verekitug corporate update, Oct 11, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Capital (as filed)

Cash
$47.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$160M Sep 30, 2026
Operating cash flow
−$54.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$207M cash, runway through 2027 per the deep dive of Nov 10, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Upstream Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Upstream Bio (UPB) - Scientific Deep Dive for Verekitug and Pipeline Products Verekitug has two positive Phase 2s at near-zero enterprise value, but the Phase 3 appears mis-specified for a broad label, uses an untested dose, faces longer-acting competitors already in Phase 3, and requires a certain large dilutive financing before any data.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (15)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)